| scholarly article | Q13442814 |
| P50 | author | Clemens O. Hanemann | Q46766795 |
| P2093 | author name string | Sylwia Ammoun | |
| Paul Manley | |||
| Marei Caroline Schmid | |||
| Joceline Triner | |||
| P2860 | cites work | Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients | Q47692368 |
| Differential gene expression between human schwannoma and control Schwann cells. | Q54573044 | ||
| Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells | Q73424194 | ||
| Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis | Q77437697 | ||
| Imatinib mesylate | Q82507538 | ||
| Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors | Q27658951 | ||
| Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL | Q28246204 | ||
| News on the genetics, epidemiology, medical care and translational research of Schwannomas | Q28283074 | ||
| ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma | Q30474678 | ||
| Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia | Q33382564 | ||
| Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity | Q36445494 | ||
| Magic but treatable? Tumours due to loss of merlin. | Q36972789 | ||
| Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. | Q39807616 | ||
| Imatinib induces apoptosis by inhibiting PDGF- but not insulin-induced PI 3-kinase/Akt survival signaling in RGC-5 retinal ganglion cells. | Q39810675 | ||
| Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate). | Q39840621 | ||
| Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma | Q40075297 | ||
| EGFR phosphorylation-dependent formation of cell-cell contacts by Ras/Erks cascade inhibition | Q40157531 | ||
| Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation | Q40593443 | ||
| Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation | Q40617267 | ||
| Growth factors in mechanisms of malignancy: roles for TGF-beta and FGF. | Q41155490 | ||
| Reduced apoptosis rates in human schwannomas. | Q42475808 | ||
| Imatinib targets PDGF signaling in melanoma and host smooth muscle neighboring cells. | Q43046973 | ||
| Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib | Q43239053 | ||
| Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244. | Q43266903 | ||
| Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors | Q46630294 | ||
| Postnatal Schwann cell proliferation but not myelination is strictly and uniquely dependent on cyclin-dependent kinase 4 (cdk4). | Q46810958 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 759-766 | |
| P577 | publication date | 2011-07-01 | |
| P1433 | published in | Neuro-Oncology | Q15724471 |
| P1476 | title | Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2 | |
| P478 | volume | 13 |
| Q92505476 | An update on the CNS manifestations of neurofibromatosis type 2 |
| Q46412577 | Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival. |
| Q50352494 | Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2. |
| Q30364937 | Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies. |
| Q57266579 | Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2 |
| Q57172733 | Contemporary Molecular Biology of Sporadic Vestibular Schwannomas: A Systematic Review and Clinical Implications |
| Q30389069 | Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma |
| Q37885731 | Emerging therapeutic targets in schwannomas and other merlin-deficient tumors |
| Q30407175 | Imatinib in neurofibromatosis type 2. |
| Q28728224 | Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells |
| Q38010858 | Merlin, a multi-suppressor from cell membrane to the nucleus |
| Q35218073 | Neurofibromatosis-related tumors: emerging biology and therapies |
| Q42223215 | Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells |
| Q38770185 | Radiation-Induced Schwannomas and Neurofibromas: A Systematic Review. |
| Q36189820 | Role of Merlin/NF2 inactivation in tumor biology |
| Q38180808 | Schwannomas and their pathogenesis |
| Q34393461 | Targeting the PDGF signaling pathway in tumor treatment |
| Q38666243 | The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma. |
| Q41135859 | The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours |
| Q42509945 | The role of insulin-like growth factors signaling in merlin-deficient human schwannomas. |
| Q30357776 | Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis |
Search more.